免疫抑制治疗在IgA肾病中是否有作用?
IgA肾病是全球最常见的原发性肾小球疾病,约40%患者进展至肾衰竭。由于缺乏大型临床试验网络和疗效替代标志物,相关大型多中心试验较少。本文综述了评估免疫抑制治疗IgA肾病疗效的最新临床研究,指出近期试验支持疾病参数改善,但未必平行转化为长期结局改善。
要点
- IgA肾病约40%患者进展至肾衰竭,免疫抑制治疗的理论基础与黏膜免疫调节缺陷和炎症相关。
- 近期临床试验支持免疫抑制改善疾病参数,但未始终转化为长期结局的平行改善。
- 缺乏大型临床试验网络和疗效替代标志物是IgA肾病大型多中心试验较少的原因。
核心结论
- 免疫抑制治疗IgA肾病有理论基础,近期试验支持疾病参数改善,但未必平行改善长期结局。
研究设计与样本
- 综述,总结评估免疫抑制治疗IgA肾病疗效的最新临床研究。
主要发现
- IgA肾病约40%患者进展至肾衰竭。
- 近期临床试验支持疾病参数改善,但未始终转化为长期结局的平行改善。
局限性
- 缺乏大型临床试验网络和疗效替代标志物,导致大型多中心临床试验较少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The most common primary glomerular disease globally is IgA nephropathy (IgAN). It is often a slowly progressive disease, and ∼40% of patients will progress to kidney failure. Due to a lack of large clinical trial networks and a lack of surrogate markers of treatment efficacy, there are relatively few large multicenter clinical trials in IgAN. Given that both the pathogenesis and progression of IgAN are linked to defects in mucosal immune regulation and inflammation, use of immunosuppression to prevent kidney failure is well founded. However, recent clinical trials have supported improvement in disease parameters, but this has not always translated to parallel amelioration in longer-term outcome. In this review we summarize the most current clinical research examining the efficacy of immunosuppression in IgAN.
引用
- Al-Lawati AI, Reich HN. Is there a role for immunosuppression in immunoglobulin A nephropathy? Nephrol Dial Transplant. 2017. PMID: 28391341. doi:10.1093/ndt/gfw342
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。